Literature DB >> 8690414

Inhibition of experimentally induced cirrhosis in rats by hypothyroidism.

R Oren1, I Dotan, M Papa, Y Marravi, H Aeed, J Barg, L Zeidel, R Bruck, Z Halpern.   

Abstract

The coexistence of hyperkinetic circulation, hypermetabolism, and hyperactivity of the sympathetic nervous system is encountered in both cirrhosis and hyperthyroidism. Several drugs, such as propylthiouracil and propranolol, that are beneficial for treating some patients with chronic liver diseases are also prescribed for the treatment of thyrotoxicosis. We investigated the effects of experimentally induced hypo- and hyperthyroidism on the development of cirrhosis induced in rats by thioacetamide (TAA). We specifically examined whether hypothyroidism could prevent and hyperthyroidism could aggravate liver damage. Hypothyroidism induced by methimazole (MMI, 0.04%), propylthiouracil (PTU 0.05%), and by thyroidectomy was confirmed by a significant elevation of thyroid-stimulating hormone (TSH) levels. Hyperthyroidism (decreased TSH levels) was induced by eltroxin (ELT:50 micrograms/kg). Thirteen groups of 10 rats each were studied: euthyroid controls (3 groups: water, TAA 1.5 months, and TAA 3 months), hypothyroid (6 groups: MMI, PTU, surgical, MMI-TAA, PTU-TAA, surgical-TAA), and hyperthyroid (4 groups:ELT 1.5 months and 3 months, and ELT-TAA for 1.5 months and 3 months). Hepatic fibrosis (scored from 0 to 3) was significantly reduced (P < .0001) in hypothyroid rats as compared with euthyroid controls, and was aggravated in TAA-treated hyperthyroid rats (P < .0001). Quantitative microscopic analysis of liver biopsy specimens from all groups confirmed the semiquantitative histopathological scores (P < .001). Direct intrasplenic pressure measurement revealed a significant portal pressure elevation in the TAA and the ELT-treated rats (from 4.7 +/- 0.1 in the euthyroid group to 8.1 +/- 2.3 and 10.2 +/- 2.1 and 12.5 +/- 1.6 in the TAA, ELT and ELT-TAA groups, respectively). However, in the hypothyroid-TAA groups, the portal pressure was found to be within the euthyroid normal range (4.6 +/- 1.2 and 5.8 +/- 0.6 in the PTU-TAA and surgical-TAA, respectively). After 12 weeks, the mean spleen weight of rats receiving only TAA was significantly higher than the TAA-treated hypothyroid rats (P < .0001), indicating that the hypothyroid TAA-treated rats were less portal hypertensive. These results suggest that induced hypothyroidism can inhibit, whereas hyperthyroidism can aggravate, the development of cirrhosis in a rat model.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8690414     DOI: 10.1053/jhep.1996.v24.pm0008690414

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  11 in total

1.  Protective effect of Trigonella foenum-graecum on thioacetamide induced hepatotoxicity in rats.

Authors:  Seema Zargar
Journal:  Saudi J Biol Sci       Date:  2013-09-19       Impact factor: 4.219

2.  Hepatitis GB virus-C/hepatitis G virus infection in liver disease.

Authors:  I Nagata; N Tzampouras; S Chokshi; N V Naoumov; P Cheeseman; H M Smith; A J Baker; R Williams; G Mieli-Vergani
Journal:  Arch Dis Child       Date:  1997-09       Impact factor: 3.791

3.  Methimazole slows hepatocyte streaming in rats.

Authors:  R Oren; G Zajicek; Y Maaravi; G Kenet; F Karmely; A Hubert; P Raanani; N Arber
Journal:  Dig Dis Sci       Date:  1997-07       Impact factor: 3.199

Review 4.  Vitamin E management of oxidative damage-linked dysfunctions of hyperthyroid tissues.

Authors:  Paola Venditti; Lisa Di Stefano; Sergio Di Meo
Journal:  Cell Mol Life Sci       Date:  2012-12-20       Impact factor: 9.261

5.  Truncated active human matrix metalloproteinase-8 delivered by a chimeric adenovirus-hepatitis B virus vector ameliorates rat liver cirrhosis.

Authors:  Jinxia Liu; Xin Cheng; Zhengrong Guo; Zihua Wang; Dong Li; Fubiao Kang; Haijun Li; Baosheng Li; Zhichen Cao; Michael Nassal; Dianxing Sun
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

6.  Lack of the matricellular protein SPARC (secreted protein, acidic and rich in cysteine) attenuates liver fibrogenesis in mice.

Authors:  Catalina Atorrasagasti; Estanislao Peixoto; Jorge B Aquino; Néstor Kippes; Mariana Malvicini; Laura Alaniz; Mariana Garcia; Flavia Piccioni; Esteban J Fiore; Juan Bayo; Ramón Bataller; Elizabeth Guruceaga; Fernando Corrales; Osvaldo Podhajcer; Guillermo Mazzolini
Journal:  PLoS One       Date:  2013-02-11       Impact factor: 3.240

7.  Utilization of murine laparoscopy for continuous in-vivo assessment of the liver in multiple disease models.

Authors:  Yami Shapira; Meirav Katz; Muhammad Ali; Michael Kaplan; Eli Brazowski; Zamir Halpern; Eran Elinav
Journal:  PLoS One       Date:  2009-03-10       Impact factor: 3.240

8.  The Immune Interplay between Thyroid Papillary Carcinoma and Hepatic Fibrosis.

Authors:  Nidal Muhanna; Johnny Amer; Ahmad Salhab; Jean-Yves Sichel; Rifaat Safadi
Journal:  PLoS One       Date:  2015-07-07       Impact factor: 3.240

9.  Propylthiouracil prevents cutaneous and pulmonary fibrosis in the reactive oxygen species murine model of systemic sclerosis.

Authors:  Gianluca Bagnato; Alessandra Bitto; Natasha Irrera; Gabriele Pizzino; Donatella Sangari; Maurizio Cinquegrani; William Roberts; Marco Atteritano; Domenica Altavilla; Francesco Squadrito; Gianfilippo Bagnato; Antonino Saitta
Journal:  Arthritis Res Ther       Date:  2013-09-16       Impact factor: 5.156

10.  The abnormality of thyroid hormones in patients with type A hepatic encephalopathy.

Authors:  Lin Wang; Wanyou Yu; Wukui Cao; Wei Lu
Journal:  Oncotarget       Date:  2017-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.